AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2407144
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia (bupivacaine 0.25% and fentanyl 2 micrograms/ml, infused at 6-10 ml/h for 76:1.45 h)
Trial: 7437747
Drug: Gas-powered jet
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gas-powered jet injection
Trial: 20028464
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (sham acupuncture)
Trial: 27476252
Drug: Intravenous traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous traditional oxytocin infusion
Trial: 25110677
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (1 mL of testosterone enanthate 250 mg/mL) once every four weeks for 12 weeks
Trial: 25110677
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mL of 0.9% wt/vol NaCl) once every four weeks for 12 weeks
Trial: 22392565
Drug: Reduced-dose chemotherapy
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose chemotherapy (elimination of 2 induction drugs and 3 months of maintenance therapy from the standard regimen)
Trial: 18809309
Drug: Pattern analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pattern analysis of biomarker molecules from blood samples
Trial: 18809309
Drug: Optimized therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized therapy decision based on diagnostic tools
Trial: 17315527
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections (MDI) of glargine
Trial: 3301155
Drug: Nicardipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (20 or 40 mg t.i.d.)
Trial: 26129996
Drug: Culturally Adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally Adapted Cognitive-Behavioral Therapy (CA-CBT)
Trial: 23836044
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics (AB) - amoxicillin and metronidazole three times a day for 7 days
Trial: 23836044
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) - two applications on the day of SRP and at follow-up after 7 days
Trial: 2243674
Drug: Ketorolac ophthalmic
RxNorm normalized name: ketorolac ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac ophthalmic solution (NSAID)
Trial: 23657629
Drug: Melanoma vaccine
RxNorm normalized name: melanoma vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melanoma vaccine in incomplete Freund's adjuvant (IFA)
Trial: 21177791
Drug: Daily transdermal
RxNorm normalized name: Deponit 0.2 MG/HR Daily Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily transdermal DHT gel
Trial: 19725341
Drug: Fascia iliaca
RxNorm normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascia iliaca compartment block with 0.45% ropivacaine at a dosage of 0.3 mL/kg (maximum dose, 30 mL)
Trial: 17623694
Drug: Iclaprim (AR-100)
RxNorm normalized name: iclaprim
DrugBank: Iclaprim (DB06358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iclaprim (AR-100) 1.6 mg/kg intravenous infusion
Trial: 7812305
Drug: Fiuggi water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiuggi water (more than 1500 ml/die) for 7 and 14 days
Trial: 7812305
Drug: Fiuggi water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiuggi water (less than 1500 ml/die) for 7 and 14 days
Trial: 2978287
Drug: Protein meal
RxNorm normalized name: REAL FOOD BLENDS Select High Protein Meal 1.6 Cal/mL Enteral Suspension (Turkey Pear Pumpkin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein meal (1-1.5 g of protein/kg)
Trial: 20694508
Drug: Family Cognitive-Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Cognitive-Behavioral Therapy (FCBT)
Trial: 16879931
Drug: Gabapentin 3200
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 3200 mg/day
Trial: 16879931
Drug: Cocaine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (0, 12, 25, 50 mg)
Trial: 16879931
Drug: Gabapentin 0
RxNorm normalized name: Capsaicin/Menthol/Methyl Salicylate;Gabapentin 0.0375%-5%-20%; 300 MG Multiple Routes Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 0 mg/day (placebo)
Trial: 15319143
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg Mg++ daily (group A)
Trial: 15319143
Drug: No supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplement (group B)
Trial: 7923309
Drug: Benazepril 10
RxNorm normalized name: benazepril 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 10 mg twice daily (increased to 20 mg twice daily if necessary)
Trial: 3044508
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cholestyramine and bezafibrate
Trial: 31974533
Drug: Riociguat treatment
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riociguat treatment after 5 months
Trial: 31974533
Drug: Riociguat treatment
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riociguat treatment after 11.2 months
Trial: 28126491
Drug: Non-nutritive sweetened
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-nutritive sweetened beverage (NSB; sucralose; 4 g)
Trial: 28126491
Drug: Sugar-sweetened beverage
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-sweetened beverage (SSB; sucrose; 31 g)
Trial: 26006702
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral immediate-release onapristone after an overnight fast
Trial: 26006702
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral immediate-release onapristone within 30 min of a high-fat, high-calorie meal
Trial: 26006702
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral immediate-release onapristone
Trial: 20367670
Drug: Pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dye laser therapy after 60-90 min ALA application
Trial: 16308351
Drug: Intravenous isoproterenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous isoproterenol (isoprenaline): 6, 12 and 24 ng (kg fat‐free mass)‐1 min‐1
Trial: 16308351
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (vitamin C; 0.04 g (kg fat‐free mass)‐1)
Trial: 9088775
Drug: Insulin Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Lispro (LP)
Trial: 9088775
Drug: Human Insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human Insulin (H)
Trial: 9088775
Drug: Porcine Insulin
RxNorm normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine Insulin (P)
Trial: 8462534
Drug: Intravenous diclofenac,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diclofenac, 100 mg
Trial: 29905973
Drug: Teriparatide 20 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide 20 μg/d plus sham vibration 10 min/d (n=20)
Trial: 29905973
Drug: Teriparatide 20 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide 20 μg/d plus vibration 10 min/d (n=21)
Trial: 29905973
Drug: Teriparatide 20 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide 20 μg/d after 12-month extension
Trial: 27196589
Drug: Split-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose regimen
Trial: 25207759
Drug: Temperature-modulated photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temperature-modulated photodynamic therapy (PDT) with 20% ALA and 10 J/cm, 417-nm blue light, heated during incubation
Trial: 22776824
Drug: Dapagliflozin 1
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 1 mg
Trial: 20055989
Drug: Lower tidal
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower tidal volume (6 ml/kg)
Trial: 20055989
Drug: Conventional tidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional tidal volume (10 ml/kg)
Trial: 8810613
Drug: AutoSet nCPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AutoSet nCPAP titration
Trial: 4020121
Drug: timolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: timolol (10 mg/day, n = 14)
Trial: 4020121
Drug: methyldopa (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methyldopa (250 mg/day, n = 16)
Trial: 4020121
Drug: hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (25 mg/day) and amiloride (2.5 mg/day)
Trial: 26729245
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy (hydroxychloroquine, methotrexate, mycophenolate mofetil, prednisolone) in addition to standard topical therapy
Trial: 26729245
Drug: Topical therapy
RxNorm normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical therapy plus a short course of prednisolone given orally
Trial: 17914310
Drug: Fusidic acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic acid (4 mg/mL) and heparin (10 IU/mL) lock
Trial: 17914310
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no fusidic acid-heparin lock)
Trial: 16182311
Drug: Ranitidine 50
RxNorm normalized name: ranitidine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 50 mg i.v. eight hourly
Trial: 16182311
Drug: Sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1 g six hourly
Trial: 29632995
Drug: Trimodulin (42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimodulin (42 mg IgM/kg/day)
Trial: 24122814
Drug: CSL112 (3.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL112 (3.4 g or 6.8 g, administered intravenously once or twice weekly)
Trial: 24122814
Drug: CSL112 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL112 (multiple infusions)
Trial: 24122814
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered intravenously)
Trial: 21219987
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg of haemagglutinin (HA) of each of three influenza strains on days 0 and 14
Trial: 21219987
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg of haemagglutinin (HA) on day 0 and saline placebo on day 14
Trial: 21219987
Drug: Both vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccine dose groups
Trial: 6437286
Drug: Diazepam (0.29
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.29 mg/kg, iv) + Physostigmine
Trial: 6437286
Drug: Morphine (0.21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.21 mg/kg, iv) + Physostigmine
Trial: 6437286
Drug: Physostigmine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine alone (3 mg, iv)
Trial: 27323608
Drug: Jiangzhi Xiaoban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiangzhi Xiaoban Tablet (JXT), 0.45 g/tablet, 4 tablets each time, 3 times per day for 8 weeks
Trial: 27323608
Drug: Simvastatin Tablet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin Tablet, 20 mg/tablet, 1 tablet each time, once per evening for 8 weeks
Trial: 24497220
Drug: Brotizolam 0.25
RxNorm normalized name: brotizolam 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam 0.25 mg/day
Trial: 17413465
Drug: Active mobilization
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active mobilization program (Mechanical Diagnosis and Therapy)
Trial: 14723508
Drug: Bronchodilator drug
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator drug (Terbutaline)
Trial: 11028835
Drug: 5-HT3 receptor
RxNorm normalized name: 5-HT3 receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT3 receptor antagonists (specifically 2 mg intravenous tropisetron)
Trial: 1622045
Drug: Desmopressin (DDAVP)
RxNorm normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin (DDAVP) 0.3 microgram/kg infusion over 15 min after cardiopulmonary bypass
Trial: 1622045
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion over 15 min after cardiopulmonary bypass
Trial: 6090539
Drug: Topical acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical acyclovir therapy
Trial: 23710796
Drug: Cognitive rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation (10 therapy sessions over 3 months, followed by 4 maintenance sessions over 6 months)
Trial: 22025630
Drug: Bedtime dosing
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime dosing of at least one BP-lowering medication
Trial: 15339577
Drug: Fuzheng Huayu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzheng Huayu Capsule (FZHY Capsule)
Trial: 15339577
Drug: Heluo Shugan
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heluo Shugan Capsule (Control)
Trial: 10898841
Drug: Implant-supported overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported overdentures on a transmandibular implant system (n = 21)
Trial: 10898841
Drug: Implant-mucosa-supported overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-mucosa-supported overdentures on 2 IMZ implants (n = 20)
Trial: 9151586
Drug: Bioceram sapphire
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bioceram sapphire implants with overdentures
Trial: 1358044
Drug: Nebivolol 1
RxNorm normalized name: nebivolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 1 mg/day for 48 hours
Trial: 1358044
Drug: Nebivolol 2.5
RxNorm normalized name: nebivolol 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 2.5 mg/day for 72 hours
Trial: 1358044
Drug: Nebivolol 2.5
RxNorm normalized name: nebivolol 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 2.5 mg for one week then 5 mg for 5 weeks
Trial: 9818307
Drug: Reminiscence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminiscence therapy (RT)
Trial: 29920323
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g high molecular weight oat β-glucan
Trial: 23852152
Drug: High-dose atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose atorvastatin (80 mg) associated with double-dose clopidogrel (150 mg)
Trial: 23852152
Drug: Double-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose clopidogrel alone
Trial: 21048432
Drug: Mixed model
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed model for cholesterol-reducing treatments
Trial: 21048432
Drug: General linear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General linear model for cholesterol-reducing treatments
Trial: 21048432
Drug: Mixed model
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed model for sleeplessness treatments
Trial: 21048432
Drug: General linear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General linear model for sleeplessness treatments
Trial: 20179692
Drug: Biofeedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback therapy (manometric‐assisted pelvic relaxation and simulated defecation training)
Trial: 10193351
Drug: Intrapleural streptokinase,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural streptokinase, 250,000 IU daily for three days
Trial: 3393781
Drug: Ciprofloxacin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (oral administration)
Trial: 3393781
Drug: Cefotaxime (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (intravenous administration)
Trial: 26444334
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection (i.v.) of PHC
Trial: 26444334
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection (i.m.) of PHC
Trial: 21820860
Drug: 1.0mg fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0mg fluoride tablet (Group A)
Trial: 21820860
Drug: 0.5mg fluoride
RxNorm normalized name: Quflora Pediatric with 0.5mg Fluoride Quatrefolic Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg fluoride tablet (Group B)
Trial: 16620590
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose (5 microg) after negative conversion of anti-HBs
Trial: 16620590
Drug: Intradermal revaccinees
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal revaccinees
Trial: 16620590
Drug: Intramuscular revaccinees
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular revaccinees
Trial: 9212136
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg epidural morphine preemptively 60 min before surgery
Trial: 9212136
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg epidural morphine at the conclusion of surgery
Trial: 3296607
Drug: Aminophylline (5.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (5.6 mg x kg‐1)
Trial: 3296607
Drug: Thiopental (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (7 mg x kg‐1)
Trial: 28134053
Drug: r-tPA treatment
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-tPA treatment
Trial: 26013140
Drug: Anaesthetics and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaesthetics and lavage (50 mL saline)
Trial: 21718959
Drug: Ulinastatin 150,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin 150,000 U twice daily for 3 days
Trial: 19065051
Drug: Titration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration of inspired oxygen (FiO(2)) alone
Trial: 14656717
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (1.26 micromol.kg(‐1).min(‐1) x 6 h, n = 9)
Trial: 14656717
Drug: Physiological dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological dose of insulin (1 mU.kg(‐1).min(‐1) euglycemic hyperinsulinemic clamp x 2 h, n = 6)
Trial: 14656717
Drug: Pharmacological dose
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological dose of insulin (20 mU.kg(‐1).min(‐1) euglycemic hyperinsulinemic clamp x 2 h, n = 9)
Trial: 9661645
Drug: GHRH plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH plus GHRP-6 (90 micrograms each, administered intravenously as a bolus)
Trial: 56591
Drug: Transfusion to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion to a Hb of 10‐12 g/dl (group A)
Trial: 56591
Drug: Moderate hypertransfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate hypertransfusion to a Hb of 14‐16 g/dl (group B)
Trial: 31758247
Drug: GI‐pill gastrointestinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GI‐pill gastrointestinal electronic capsule
Trial: 31758247
Drug: X‐ray granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: X‐ray granule capsule
Trial: 22939518
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lisinopril and irbesartan (n = 70)
Trial: 22939518
Drug: Lisinopril (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (n = 35)
Trial: 22939518
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lisinopril and irbesartan
Trial: 19969216
Drug: Topical moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical moxifloxacin 0.5% drops